Ratings Johnson & Johnson Buenos Aires S.E.

Equities

JNJ

ARDEUT110236

End-of-day quote Buenos Aires S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
12,831 ^ARS	+6.25%		+15.18%	+26.61%

08:03pm	Some of the biggest splits in Corporate America	RE
05-22	Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies	RE

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
The company's enterprise value to sales, at 4.1 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JOHNSON & JOHNSON	+26.61%	369B	-
ELI LILLY AND COMPANY	+38.69%	723B	C+
NOVO NORDISK A/S	+34.28%	595B	B
MERCK & CO., INC.	+20.24%	332B	B-
ABBVIE INC.	+2.12%	282B	C+
ASTRAZENECA PLC	+17.02%	244B	B+
NOVARTIS AG	+9.31%	208B	B-
ROCHE HOLDING AG	-5.07%	205B	A+
PFIZER, INC.	-0.35%	168B	C+
AMGEN INC.	+6.42%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes